Abstract:Objective:To test our hypothesis that reversion of insulin resistance by rhein might contribute to its therapeutic effect on diabetic nephropathy(DN) the effects of rhein and rosiglitazone on metabolic disorders and renal lesion in diabetic db/db mice were compared, and the mechanism of rhein on preventing the development of DN was also investigated Methodology:Diabetic db/db mice were continuously treated with rhein 120mg/(kg·d) or rosiglitazone 4mg/(kg·d) for 12 weeks The body weight, serum glucose and lipid were detected at the end of the study Renal histopathology was evaluated under light microscopy and immunohistochemistry staining Mitochondrial morphology was observed under electronic microscopy The expression of mRNA was determined by real time RT PCR Results:Compared with the untreated diabetic conrols, both of rhein and rosiglitazone led to similar amelioration of glomerular mesangial expansion and extracelluar matrix accumulation, as well as reduction of blood glucose level However, the diverse changers were observed in lipid metabolism after two agents treatment Rhein markedly decreased the body weight of mice [(45 0±2 60g vs (49 9±1 00g, P 0 01] and the level of plasma cholesterols [(2 1±0 20 vs (2 8±0 6 mmol/L, P 0 01], while rosiglitazone significantly increased the body weight [(52 9±2 2g vs (49 9±1 0g, P 0 01] and cholesterols [(5 5±0 6 vs (2 8±0 6 mmol/L, P 0 01] The level of low density lipoprotein (LDL was also enhanced after rosiglitazone treatment [(0 45±0 11 vs (0 13±0 04 mmol/L, P 0 01] while mild fell after rhein treatment The number of mitochondrial was decreased and the structure blurry in renal tubular epithelia from db/db mice, and which were markedly ameliorated by rhein and mildly by rosiglitazone The expression of PPARγ was down regulated in the fat and muscle of db/db mice, while up regulated after both rhein and rosiglitazone treatment The expression of resistin, a linkage between obesity and insulin resistance, was unexpectantly reduced in db/db mice and mildly decreased in fat and markedly increased in muscle after rhein or rosiglitazone treatment, confusing the role of resistin on insulin resistance The expression of fatty acid translocase (FAT/CD36) was found to be up regulated in fat and muscle of db/db mice, and attenuated by both two agents However, the effect of rhein was much more stronger than rosiglitazone Conclusion:The similar renal protective effect of rhein compared with rosiglitazone gave the evidence that reversion of insulin resistance was attributed to the prevention of DN In addition, the improvement of lipidemia by rhein might provide a better way for diabetic metabolic disorders than by rosiglitazone, which was shown an adverse consequence of hyperlipidemia and weight gain

Related Mechanisms of Rhein Improving Glucose and Lipid Metabolism

Rhein for treating diabetes mellitus: A pharmacological and mechanistic overview

The Molecular Mechanism of Rhein in Diabetic Nephropathy

Rhein Improves Renal Lesion and Ameliorates Dyslipidemia in Db/Db Mice with Diabetic Nephropathy

Improvement of Glucose Tolerance by Rhein with Restored Early-Phase Insulin Secretion in Db/db Mice

Gut Microbiota Play an Essential Role in the Antidiabetic Effects of Rhein

Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway.

Rhein Protects Pancreatic Beta-Cells From Dynamin-Related Protein-1-Mediated Mitochondrial Fission And Cell Apoptosis Under Hyperglycemia

Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice

Rhein protects retinal Müller cells from high glucose-induced injury via activating the AMPK/Sirt1/PGC-1α pathway

Effect of Rhein on Glucose Transporter-1 Expression and Its Function in Glomerular Mesangial Cells.

[Effect of Early Intervention with Rhein on Islet Function in Db/db Mice].

Improvement of Diabetic Metabolic Disorders Ameliorate the Renal Lesion in Db/db Mice:Comparison Between Rhein and Rosiglitazone

Rhein alleviates advanced glycation end products (AGEs)-induced inflammatory injury of diabetic cardiomyopathy in vitro and in vivo models

The influence of rhein on the absorption of rehmaionoside D: In vivo, in situ, in vitro, and in silico studies

Rhein targets macrophage SIRT2 to promote adipose tissue thermogenesis in obesity in mice

Identification and action mechanism of lipid regulating components from Rhei Radix et rhizoma

A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient

Early effect of rhein on insulin secretion in db/db mice

Rehmannia Glutinosa (gaertn.) DC. Polysaccharide Ameliorates Hyperglycemia, Hyperlipemia and Vascular Inflammation in Streptozotocin-Induced Diabetic Mice.

Update on Pharmacological Activities, Security, and Pharmacokinetics of Rhein